Provider of diagnostic tools to support personalized cancer treatment. The company has developed prognostic, diagnostic, and predictive tests for lung cancer, colorectal cancer, and prostate cancer. Its colon cancer test ColoFast is a blood-based miRNA test for early detection of colon cancer. It is also developing DiagnoLung which is a blood-based ELISA test that measures the level of three protein biomarkers to screen high-risk patients for non-small-cell lung cancer. The company operates in the Genomics sector with additional focus on Oncology and Clinical Genomics. Its business model centers on Lung cancer. Founded in 2010, headquartered in Madrid, Spain. The company has raised $6.9M at the Series A stage. Backed by investors including Europa, CRB Inverbio, Inveready, Alentia, EIC Fund and others.
← All startups
Amadix
Series AProvider of diagnostic tools to support personalized cancer treatment. The company has developed prognostic, diagnostic, and predictive tests for lung cancer, colorectal cancer, and prostate cancer. Its colon cancer test ColoFast is a blood-based miRNA test for early detection of colon cancer. It is also developing DiagnoLung which is a blood-based ELISA test that measures the level of three protein biomarkers to…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Lung cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA and RNA
Institutional investors
EuropaCRB InverbioInvereadyAlentiaEIC FundEuropean Investment BankClaveGENESIS BiomedDesafiaEIT Health
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.